



Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 40791

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension

Denise Schaffner, Adhara Lazaro, Peter Deibert, Peter Hasselblatt, Patrick Stoll, Lisa Fauth, Manfred W Baumstark, Irmgard Merfort, Annette Schmitt-Graeff, Wolfgang Kreisel

Abstract

AIM

Match Overview

- 1 **Crossref** 86 words 2%
Denise Schaffner, Dominik von Elverfeldt, Peter Deibert, Adhara Lazaro et al. "Phase-contrast MR flow imaging: A tool t
- 2 **Internet** 13 words <1%
crawled on 13-Mar-2016
www.science.gov
- 3 **Crossref** 13 words <1%
Senbel, Amira M., Ahmed M. Hashad, Fouad M. Sharabi, and Tahia T. Daabees. "Combined effect of sildenafil and gua
- 4 **Publications** 12 words <1%
"Studies from Leiden University in the Area of Proinsulin I...
escribed (Short-term high-fat diet increas", *Diabetes Week*,

找到约 30,600 条结果 (用时 0.74 秒)

Novel treatment options for portal hypertension - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421460/> - [翻译此页](#)

作者: P Schwabl - 2017 - 被引用次数: 5 - [相关文章](#)

2017年4月18日 - Portal hypertension is most frequently associated with cirrhosis and is a ... these strategies are far from satisfactory and only target splanchnic hyperemia. and amelioration of liver fibrosis in animals treated with ET-receptor antagonists. ... in splanchnic resistance by affecting RhoA and NO pathways [55].

Future therapy of portal hypertension in liver cirrhosis – a guess

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191223/> - [翻译此页](#)

作者: T Sauerbruch - 2014 - 被引用次数: 15 - [相关文章](#)

2014年10月1日 - In patients with chronic liver disease, portal hypertension is driven by ... in the portal vein exceeding the vena cava pressure by more than 5 mm Hg [1]. to portal hypertension and its complications, as suggested by animal models [41–47]. do not fall into biological pathways known to be involved in liver ...

缺少字词: phosphodiesterase

Alterations in the NO-cGMP pathway may contribute to the.... AASLD ...

liverlearning.aasld.org/.../thelivermeeting/.../denise.schaffner.alterations.in.th... - [翻译此页](#)

2017年10月20日 - Background: Liver cirrhosis is associated with an imbalance between ... muscle tone, may yield information on the pathophysiology of portal hypertension. 14 treated animals: 0.03g TAA/100ml drinking water for 16 weeks). ... and inducible NO synthase (eNOS and iNOS), phosphodiesterase 5 (PDE5), ...

缺少字词: target

Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

<https://link.springer.com/content/pdf/10.1007%2Fs10620-017-4903-5.pdf> - [翻译此页](#)

2018年1月22日 - Experimental studies indicate that the hydrostatic pressure in hepatic line-

[全部](#)[图片](#)[新闻](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 48,700 条结果 (用时 0.59 秒)

Disrupted Pulmonary Artery Cyclic Guanosine Monophosphate ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930949/> - [翻译此页](#)

作者: KJ Lee - 2014 - 被引用次数: 28 - [相关文章](#)

Our results **indicate** that prolonged hyperoxia leads to lung injury, PH, RVH, **and** disrupted ... This **pathway** offers multiple attractive **potential targets** for **treatment**, **and** inhaled **nitric oxide** normalize **phosphodiesterase 5** expression **and** activity in ... **treatment for pulmonary hypertension** in infants **with** chronic lung **disease**.

Role of cGMP Signaling and Phosphodiesterase-5 inhibitors in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230443/> - [翻译此页](#)

作者: RC Kukreja - 2012 - 被引用次数: 58 - [相关文章](#)

Cyclic guanosine 3',5'-monophosphate (cGMP) is a critical intracellular ... Two isoforms of GCs exist in vertebrate cells **and** tissues: a **nitric oxide** ... made PDE-5 an important drug **target** for the **treatment** of erectile dysfunction (6), ... Revatio™ **and** Adcirca™ have also been approved for **treatment of pulmonary hypertension**.

CGMP-specific phosphodiesterase type 5 - an overview ...

<https://www.sciencedirect.com/topics/.../cgmp-specific-phosphodiesterase-typ...> - [翻译此页](#)

Cyclic GMP binds to subdomain A, but binding of this nucleotide to ... the free cGMP levels in PDE5-regulated signaling **pathways**, the number **and** affinity of ... Pathophysiology of Persistent **Pulmonary Hypertension** of the Newborn ... axis is a very promising **target** for the **treatment** of hypertrophy **and** heart **failure** patients.

Phosphodiesterase inhibitors for the treatment of pulmonary ...

erj.ersjournals.com/content/32/1/198 - [翻译此页](#)

作者: MR Wilkins - 2008 - 被引用次数: 135 - [相关文章](#)

2008年5月8日 - These include **nitric oxide** **and** the natriuretic peptide family (atrial, brain **and** ... of cGMP metabolism by **phosphodiesterase type 5 (PDE5)-targeted** ... is the **potential** of sildenafil to

找到约 48,600 条结果 (用时 0.71 秒)

Cyclic guanosine monophosphate signalling pathway in pulmonary ...

<https://www.ncbi.nlm.nih.gov/pubmed/22982057> ▼ 翻译此页

作者: CN Chen - 2013 - 被引用次数: 11 - 相关文章

2012年9月12日 - Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. ... drug target for the treatment of pulmonary arterial hypertension (PAH). ... to natriuretic peptides or nitric oxide (NO), cGMP transduces its effects ... including cGMP-regulated phosphodiesterases and protein kinases.

Role of cGMP Signaling and Phosphodiesterase-5 inhibitors in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230443/> ▼ 翻译此页

作者: RC Kukreja - 2012 - 被引用次数: 58 - 相关文章

Cyclic guanosine 3',5'-monophosphate (cGMP) is a critical intracellular ... Two isoforms of GCs exist in vertebrate cells and tissues: a nitric oxide ... made PDE-5 an important drug target for the treatment of erectile dysfunction (6), ... Revatio™ and Adcirca™ have also been approved for treatment of pulmonary hypertension.

[PDF] Therapeutic Potentials of Phosphodiesterase-5 ... - MedReviews

medreviews.com/sites/default/files/2017-02/RICM152_158.pdf ▼ 翻译此页

Drug Administration for the treatment of erectile dysfunction and more recently ... involving nitric oxide, cyclic guanosine monophosphate, and protein kinase G, ... various tissues and systemic vasculature make them potential targets in a ... heart disease, doxorubicin cardiomyopathy, and pulmonary arterial hypertension.

Phosphodiesterase-5 inhibitors: Raynaud's and beyond Phatak S ...

www.indianjrheumatol.com/article.asp?issn=0973-3698;year..6;... - 翻译此页

作者: S Phatak - 2017 - 相关文章

2017年11月23日 - PDE5 inhibitors prevent degradation of cyclic GMP; hence, they have ... pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease hold ... (RP) and pulmonary arterial hypertension, and potential uses are emerging as ... This was mediated by effects on nitric oxide pathway, as well as ...